Inventiva (IVA) Price & Analysis

Compare

14 Followers

IVA Stock Chart & Stats

€3.30

-€0.02(-0.70%)

At close: Jan 09 4:00 PM EST

€3.30

-€0.02(-0.70%)

Day’s Range― - ―

52-Week Range€2.00 - €5.55

Previous CloseN/A

Volume1.84K

Average Volume (3M)416.07K

Market Cap

€536.06M

Enterprise Value€219.67M

Total Cash (Recent Filing)€122.08M

Total Debt (Recent Filing)€57.13M

Price to Earnings (P/E)―

Beta0.62

Next Earnings

Apr 01, 2026

EPS Estimate

-0.45

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.38

Shares Outstanding145,951,280

10 Day Avg. Volume620,713

30 Day Avg. Volume416,066

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)-1.22

Price to Sales (P/S)8.85

P/FCF Ratio-1.51

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€10.00

Price Target Upside203.03% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsEnrollment for the Phase 3 NATIV3 MASH trial is complete, positioning the trial for timely progression towards topline data.

Financial StabilityThe structured financing deal provides Inventiva with additional funding, extending operational expenses runway until the third quarter of 2026.

Regulatory ApprovalsInventiva plans to seek accelerated approval in the US and conditional approval in the EU for lanifibranor, based on a pre-specified histology analysis at 72 weeks.

Bears Say

Financial LossesIVA reported a substantial net loss, with increased SG&A expenses primarily due to personnel costs related to share-based compensation.

Research And DevelopmentDue to the prioritization of the Ph3 lanifibranor MASH program, IVA conducted a significant reduction in workforce and paused all preclinical research.

Workforce ReductionInventiva is conducting a 50% reduction in force and pausing all preclinical research, indicating a strategic shift and potential short-term challenges.

Inventiva News

Wolfe starts Inventiva at Outperform on ‘constructive’ lanifibranor view

As previously reported, Wolfe Research initiated coverage of Inventiva (IVA) with an Outperform rating and $13 price target...

6d ago

IVA

Inventiva initiated with an Outperform at Wolfe Research

Wolfe Research initiated coverage of Inventiva (IVA) with an Outperform rating and $13 price target Published first on...

6d ago

IVA

Inventiva S.A. trading resumes

14:58 EDT Inventiva (IVA) S.A. trading resumes Published first on TheFly – the ultimate source for real-time, market-moving...

14d ago

IVA

Inventiva S.A. trading halted, volatility trading pause

14:48 EDT Inventiva (IVA) S.A. trading halted, volatility trading pause Published first on TheFly – the ultimate source...

14d ago

IVA

Inventiva files $300M mixed securities shelf

16:07 EDT Inventiva (IVA) files $300M mixed securities shelf Published first on TheFly – the ultimate source for...

28d ago

IVA

Buy Rating for Inventiva: Lanifibranor’s Potential as a Foundational MASH Therapy

Analyst Ananda Ghosh of H.C. Wainwright reiterated a Buy rating on Inventiva, boosting the price target to $24.00....

1M ago

IVA

Inventiva price target raised to $24 from $20 at H.C. Wainwright

H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target on Inventiva (IVA) to $24 from $20 and...

1M ago

IVA

Inventiva’s Strategic Focus and Financial Stability Drive Buy Rating Amid Promising Phase 3 Trial Progress

Ritu Baral, an analyst from TD Cowen, maintained the Buy rating on Inventiva. The associated price target is...

1M ago

IVA

Inventiva management to meet with Piper Sandler

Meeting to be held in New York on October 8 hosted by Piper Sandler. Published first on TheFly...

1M ago

IVA

Inventiva positioned as next acquisition target, says H.C. Wainwright

H.C. Wainwright analyst Ananda Ghosh believes Inventiva’s (IVA) lanifibranor “stands out” as the only pan PPAR agonist in...

2M ago

IVA

Buy Rating for Inventiva: Lanifibranor’s Promising Role in Metabolic Disease Treatment

In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Inventiva, with a...

2M ago

IVA

Inventiva assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Ananda Ghosh assumed coverage of Inventiva (IVA) with a Buy rating and $20 price target...

2M ago

IVA

Inventiva price target raised to $13 from $9 at Guggenheim

Guggenheim raised the firm’s price target on Inventiva (IVA) to $13 from $9 and keeps a Buy rating...

2M ago

IVA

Inventiva’s Strategic Positioning and Promising Developments Drive Buy Rating

Analyst Edward Nash of Canaccord Genuity maintained a Buy rating on Inventiva, retaining the price target of $20.00....

3M ago

IVA

IVA FAQ

What was Inventiva SA’s price range in the past 12 months?

Inventiva SA lowest stock price was €2.00 and its highest was €5.55 in the past 12 months.

What is Inventiva SA’s market cap?

Inventiva SA’s market cap is €536.06M.

When is Inventiva SA’s upcoming earnings report date?

Inventiva SA’s upcoming earnings report date is Apr 01, 2026 which is in 140 days.

How were Inventiva SA’s earnings last quarter?

Inventiva SA released its earnings results on Sep 29, 2025. The company reported -€1.379 earnings per share for the quarter, missing the consensus estimate of -€0.546 by -€0.833.

Is Inventiva SA overvalued?

According to Wall Street analysts Inventiva SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Inventiva SA pay dividends?

Inventiva SA does not currently pay dividends.

What is Inventiva SA’s EPS estimate?

Inventiva SA’s EPS estimate is -0.45.

How many shares outstanding does Inventiva SA have?

Inventiva SA has 145,951,280 shares outstanding.

What happened to Inventiva SA’s price movement after its last earnings report?

Inventiva SA reported an EPS of -€1.379 in its last earnings report, missing expectations of -€0.546. Following the earnings report the stock price went down -2.178%.

Which hedge fund is a major shareholder of Inventiva SA?

Currently, no hedge funds are holding shares in FR:IVA

Company Description

Inventiva SA

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Inventiva (IVA) Earnings & Revenues

Historic Earnings Reports

IVA Stock 12 Month Forecast

Average Price Target

€10.00

▲(203.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","12":"€12","3.75":"€3.75","6.5":"€6.5","9.25":"€9.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.75,6.5,9.25,12],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2022","6":"Dec<br/>2023","9":"May<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.97,5.356923076923077,5.743846153846153,6.13076923076923,6.5176923076923075,6.904615384615385,7.291538461538462,7.678461538461538,8.065384615384616,8.452307692307691,8.839230769230769,9.226153846153846,9.613076923076923,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.97,5.356923076923077,5.743846153846153,6.13076923076923,6.5176923076923075,6.904615384615385,7.291538461538462,7.678461538461538,8.065384615384616,8.452307692307691,8.839230769230769,9.226153846153846,9.613076923076923,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.97,5.356923076923077,5.743846153846153,6.13076923076923,6.5176923076923075,6.904615384615385,7.291538461538462,7.678461538461538,8.065384615384616,8.452307692307691,8.839230769230769,9.226153846153846,9.613076923076923,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11.16,"date":1630454400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.1,"date":1646092800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.39,"date":1651363200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.39,"date":1661990400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1667260800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.514,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.875,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.165,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.78,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.165,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.59,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.97,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >